Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease hyperparathyroidism
Comorbidity C0022658|kidney disease
Sentences 37
PubMedID- 25949409 In 2004, the us food and drug administration (fda) approved cinacalcet-hcl (sensipar®, amgen) for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.
PubMedID- 20435429 Forty-six consecutive patients who underwent total parathyroidectomy (tptx) for hyperparathyroidism associated with end-stage kidney disease (ckd5) in a university hospital from 1990 to 1999 were included in a long-term observational study.
PubMedID- 22997972 Background: secondary hyperparathyroidism develops frequently with chronic kidney disease (ckd) and is associated with poor outcome.
PubMedID- 20921291 Such agents have been found to be extremely effective in controlling hyperparathyroidism in patients with advanced kidney disease [9] and in reducing mortality in patients on haemodialysis [10].
PubMedID- 22293059 Therefore, in everyday clinical practice, hypercalcemia and hyperphosphatemia often limits the ability to suppress secondary hyperparathyroidism in patients with chronic kidney disease.
PubMedID- 22503212 Background: cinacalcet (krn1493) was developed to manage secondary hyperparathyroidism in patients with chronic kidney disease.
PubMedID- 22022934 Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.
PubMedID- 26429172 Vascular calcifications represent a severe complication of secondary hyperparathyroidism in patients with chronic kidney disease (ckd) stage 5.
PubMedID- 22868729 [management of secondary hyperparathyroidism in patients with chronic kidney disease undergoing dialysis in togo].
PubMedID- 25984155 Hyperphosphataemia is an established risk factor for cardiovascular mortality, renal osteodystrophy and secondary hyperparathyroidism in patients with end-stage chronic kidney disease (ckd) under renal replacement therapy.
PubMedID- 25701941 Gene mutations in chronic kidney disease patients with secondary hyperparathyroidism and sagliker syndrome.
PubMedID- 23713879 Paricalcitol is a synthetic vitamin d2 agonist of the vdr approved for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd).
PubMedID- 22942242 The calcium-sensing receptor (casr)-specific allosteric modulator cinacalcet has revolutionized the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
PubMedID- 23222688 In the context of a pharmacokinetic (pk)/pharmacodynamic study of cinacalcet in dialysis-dependent chronic kidney disease children with secondary hyperparathyroidism, we describe the development and validation of a new, rapid, simple, and economical liquid chromatography-tandem mass spectrometry (lc-ms/ms) micromethod for quantifying cinacalcet plasma concentrations.
PubMedID- 23018042 In chronic kidney disease patients with secondary hyperparathyroidism (shpt), the recommended k/doqi target serum levels of parathyroid hormone (pth), calcium (ca) and phosphorus (p) are difficult to reach and maintain stable.
PubMedID- 21318141 Until now superiority of the third generation of pth kits, measuring only the concentration of “native” 1-84-pth, has not been proven for diagnosis of primary hyperparathyroidism, at least in patients without chronic kidney disease.
PubMedID- 25789142 [15] in fact, a reduction in 1,25(oh) 2d secondary to reduced 1-α hydroxylase enzyme activity contributes to the development of secondary hyperparathyroidism in patients with chronic kidney disease.
PubMedID- 24377047 Hifu therapy has been used in japan [50], but in other countries this therapy has been reported with contradictory results, sometimes failing [51] and sometimes showing improved results in secondary hyperparathyroidism treatment in patients with chronic kidney disease [52].
PubMedID- 25949433 This study aims to highlight the challenges in the diagnosis of hyperparathyroidism (hpt) in patients with advanced chronic kidney disease (ckd).
PubMedID- 23760489 Synthetic analogs of 1,25(oh) 2d that are less calcemic, such as paricalcitol (19-nor-1,25-dihydroxyvitamin d 2), are used to treat hyperparathyroidism associated with chronic kidney disease.
PubMedID- 24402111 [clinical protocol and therapeutic guidelines for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease].
PubMedID- 21832979 Alfacalcidol and paricalcitol are vitamin d analogs used for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease, but have known dose-dependent side effects that cause hypercalcemia and hyperphosphatemia.
PubMedID- 21058933 Importance of the field: chronic kidney disease is frequently complicated by secondary hyperparathyroidism, which causes bone disease and vascular calcification, leading to increased risk of morbidity and mortality.
PubMedID- 24884838 This report describes the activity of amg 416 in two different rodent models of uremia, compared in each case to cinacalcet, an approved therapeutic for secondary hyperparathyroidism (shpt) in patients with chronic kidney disease on dialysis.
PubMedID- 22210744 Indeed, the second-generation calcimimetic, cinacalcet, has proven clinically useful in the treatment of chronic kidney disease patients with secondary hyperparathyroidism but is not widely used in earlier stages of renal disease due to the potential to predispose such patients to hypocalcaemia and hyperphosphatemia.
PubMedID- 23140920 Considering its low incidence rate of long-term relapse, "presumed" total parathyroidectomy without autotrasplantation (tp) may be indicated for secondary hyperparathyroidism (2hpt) in patients with chronic kidney disease (ckd), not eligible for kidney transplantation.
PubMedID- 21695192 In the clinical settings, administration of 1,25(oh)2d3 is currently used as a standard of care treatment combating both 1,25(oh)2d3 deficiency and secondary hyperparathyroidism in children with chronic kidney disease-mineral and bone disorder (ckd-mbd) [9].
PubMedID- 22622503 Moreover, during the past decade, the intense research on mineral disorders, seen in the course of chronic kidney disease with secondary hyperparathyroidism, has revealed the interplay between ca(2+) and mg(2+) homeostasis.
PubMedID- 23330456 The calcimimetic agent cinacalcet is approved for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and for the treatment of hypercalcemia in patients with parathyroid carcinoma.
PubMedID- 25028644 The development of calcimimetics, which are synthetic allosteric modulators of the calcium-sensing receptor (car), has been a breakthrough in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (ckd).
PubMedID- 22007637 Background: the calcimimetic cinacalcet is approved for treating secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.
PubMedID- 25446887 Vitamin d insufficiency is prevalent in chronic kidney disease (ckd) and associated with secondary hyperparathyroidism (shpt) and increased risk of bone and vascular disease.
PubMedID- 22930877 Secondary hyperparathyroidism in patients with chronic kidney disease (ckd) is common and usually caused by associated metabolic abnormalities, in particular, hypocalcaemia and hyperphosphataemia.
PubMedID- 22015443 Background: the recently developed non-invasive high-intensity focussed ultrasound (hifu) technique for the destruction of parathyroid adenomas could also be of interest for the treatment of secondary hyperparathyroidism (shp) in patients with chronic kidney disease (ckd).
PubMedID- 21885174 Background: the efficacy of 25-hydroxyvitamin d (25[oh]d) supplementation versus vitamin d receptor activators for the treatment of secondary hyperparathyroidism (shpt) in patients with chronic kidney disease (ckd) stages 3 or 4 and vitamin d deficiency is unclear.
PubMedID- 20090879 The calcimimetic, cinacalcet, is approved for treating secondary hyperparathyroidism (shpt) in patients with chronic kidney disease (ckd) on dialysis.
PubMedID- 23960343 This study was carried out to evaluate the efficacy and safety of doxercalciferol as therapy for secondary hyperparathyroidism (shpt) in patients with chronic kidney disease (ckd) stage 4 in a prospective clinical trial.

Page: 1